Windward Bio prices IPO at $17 per share on Nasdaq

Windward Bio Group AG (WWB), a clinical-stage biotechnology company based in Basel, Switzerland, priced its initial public offering of 10,294,117 common shares at $17.00 per share, according to a press release statement.

The company has granted underwriters a 30-day option to purchase up to an additional 1,544,117 common shares at the IPO price, less underwriting discounts and commissions.

Windward Bio also announced a concurrent private placement to Sanofi Foreign Participations B.V. for an aggregate purchase price of $50.0 million, consisting of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, each at the IPO price. The combined gross proceeds from the IPO and the private placement are expected to be $225.0 million, before deducting underwriting discounts, commissions, and offering expenses.

Shares were expected to begin trading on the Nasdaq Global Select Market on Nov. 13, 2026, with the offering expected to close on Nov. 16, 2026, subject to customary closing conditions. The private placement closing is contingent on the completion of the IPO.

Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank are serving as joint book-running managers for the offering.